KRYS · Krystal Biotech, Inc.
$343.34
+10.52 (+3.16%)
At close · Aug 19
Market Cap
$9.94B
Shares
29.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$343.34
Open$339.61
Day$335.44–345.56
52W close$137.46–378.15
Avg vol 30d497K
Short int3.2M · 10.8% float · 4.2d
Short vol74%
Last earningsAug 3, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
−0%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
86%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+24%
trailing
YTD return
+39%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $344 › 200d $281 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +93 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
10.82% of float · ▼ -8.4% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
423 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
+34%
Y/Y
EPS growth
+128%
Y/Y
Free cash flow
$188.9M
Valuation
P/E 42.1
in line
Balance sheet
$492.1M
net cash
Quant / Vol
risk profile
Volatility
39%
annualized · 1-yr
Max drawdown
−17%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
Non-GAAP Research and Development ("R&D") and Selling, General a
· FY 2026
Non-GAAP
Initiated
$175M – $195M
Prior guidance
period ended
· from the Earnings Call filed Mar 31, 2024
Combined non-GAAP, R&D, and SG&A costs
· 2024
$150M – $175M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
−0%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
86%
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $344 › 200d $281 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +93 funds added
Insider flow
Distributing
Net -$8.2M over 90 days · 100% sells
Short interest
Falling
10.82% of float · ▼ -8.4% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
423 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $137
Now $343 · 86%
Range high $378
vs 200-day avg +22%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| VYJUVEK global net product revenue | $119.2M | the second quarter of 2026 | — |
| VYJUVEK gross margin | 95% | the second quarter of 2026 | — |
| VYJUVEK net product revenue since launch | $965.9M | since launch through 2Q 2026 | — |
| VYJUVEK reimbursement approvals | 730 | as of the end of 2Q 2026 | — |
| VYJUVEK unique prescribers | 640 | as of the end of 2Q 2026 | — |
| Patients prescribed VYJUVEK therapy across Germany, France, and Japan | 90 | as of the time of the press release | — |
| Reimbursement approvals for VYJUVEK in the United States | 660 | as of the time of the press release | — |
| Cash, cash equivalents, and investments | $955M | FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KRYS
this stock
Krystal Biotech, Inc.
|
$9.94B | +39.3% | +33.9% | 42.1 | 10.8% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +24.0% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +21.8% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +8.9% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KRYS | +3.2% | +1.9% | +24.2% | +0.7% | +39.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +3.6% | -1.0% | +12.7% | -2.3% | +26.5% |
Key facts
CIK
1711279
CUSIP
501147102
13F (30d)
384 filings
381 filers
Visit website
Investor relations